FCMI
NVAX icon

Foresite Capital Management II’s Novavax NVAX Stock Holding History

Foresite Capital Management II’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67,373
Closed -$14M – 3
2021
Q3 		$14M Hold
67,373
– – 4.96% 2
2021
Q2 		$14.3M Hold
67,373
– – 3.85% 2
2021
Q1 		$12.2M Hold
67,373
– – 2.81% 2
2020
Q4 		$7.51M Hold
67,373
– – 1.98% 3
2020
Q3 		$7.3M Buy
+67,373
New +$8.21M 1.59% 3

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Foresite Capital Management II's NVAX Position: Q4 2021 in Review

Foresite Capital Management II sold out of Novavax (NVAX) in Q4 2021, closing a stake of 67,373 shares — an estimated $14M sold.

Foresite Capital Management II first reported a position in NVAX in Q3 2020 and held it in 5 quarters. The position peaked at $14.3M in Q2 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • Foresite Capital Management II reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • Foresite Capital Management II sold 67,373 Novavax shares in Q4 2021, an estimated $14M.
  • Foresite Capital Management II first reported a position in Novavax in Q3 2020 and held it in 5 quarters.
  • Foresite Capital Management II's Novavax position peaked at $14.3M in Q2 2021.
  • 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Foresite Capital Management II's 13F filing for Q4 2021, filed 11 Feb 2022.